
ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise
Plus, news about Rivus, Amarin, Recordati, Liquidia, Healthcare Royalty, Lexeo, Perceptive, venBio, Novo Nordisk and Cidara:
ArriVent to start another Phase 3 of lung cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.